Aerovate Therapeutics Inc

NASDAQ AVTE

Download Data

Aerovate Therapeutics Inc Price to Book Ratio (P/B) on June 03, 2024: 5.50

Aerovate Therapeutics Inc Price to Book Ratio (P/B) is 5.50 on June 03, 2024, a 57.72% change year over year. The price to book ratio compares the market price per share of a company's stock to its book value per share. It is calculated by dividing the market capitalization by the shareholders' equity minus treasury stock, divided by the number of outstanding shares. This ratio provides insights into how the market values a company relative to its book value. A ratio above 1 indicates the market values the company more than its book value, suggesting positive market sentiment.
  • Aerovate Therapeutics Inc 52-week high Price to Book Ratio (P/B) is 7.83 on April 01, 2024, which is 42.20% above the current Price to Book Ratio (P/B).
  • Aerovate Therapeutics Inc 52-week low Price to Book Ratio (P/B) is 0.06 on March 12, 2024, which is -98.94% below the current Price to Book Ratio (P/B).
  • Aerovate Therapeutics Inc average Price to Book Ratio (P/B) for the last 52 weeks is 3.77.
NASDAQ: AVTE

Aerovate Therapeutics Inc

CEO Mr. Timothy P. Noyes M.B.A.
IPO Date June 30, 2021
Location United States
Headquarters 930 Winter Street, Waltham, MA, United States, 02116
Employees 51
Sector Healthcare
Industry Biotechnology
Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Similar companies

ADAG

Adagene Inc

NA

NA

ACRV

Acrivon Therapeutics Inc. Common Stock

NA

NA

ANTX

AN2 Therapeutics Inc

NA

NA

ANEB

Anebulo Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email